38 related articles for article (PubMed ID: 7495976)
1. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
2. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
3. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.
Addiego JE; Gomperts E; Liu SL; Bailey P; Courter SG; Lee ML; Neslund GG; Kingdon HS; Griffith MJ
Thromb Haemost; 1992 Jan; 67(1):19-27. PubMed ID: 1615478
[TBL] [Abstract][Full Text] [Related]
4. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Schwinn H; Smith A; Wolter D
Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
[TBL] [Abstract][Full Text] [Related]
5. Virus validation experiments on the production process of OCTAVI SDPlus.
Biesert L; Lemon S; Suhartono H; Wang L; Rübsamen H
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S48-54. PubMed ID: 7495968
[TBL] [Abstract][Full Text] [Related]
6. Preliminary clinical experience: pharmacokinetics and tolerance of a double-virus-inactivated factor VIII preparation.
Martinowitz U
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S84-5. PubMed ID: 7495976
[TBL] [Abstract][Full Text] [Related]
7. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
8. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
9. Review of the hepatitis A epidemics in hemophiliacs in Europe.
Vermylen J; Peerlinck K
Vox Sang; 1994; 67 Suppl 4():8-11; discussion 24-6. PubMed ID: 7831867
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission.
Robertson BH; Alter MJ; Bell BP; Evatt B; McCaustland KA; Shapiro CN; Sinha SD; Souci JM
Biologicals; 1998 Jun; 26(2):95-9. PubMed ID: 9811512
[TBL] [Abstract][Full Text] [Related]
11. [Anti-hemophilia drugs: from cryoprecipitate to factor VIII concentrates of high purity].
Gutsalo AE; Varetskaia TV; Kozulina EP; Papaian LP
Ukr Biokhim Zh (1978); 1995; 67(1):3-13. PubMed ID: 8588250
[TBL] [Abstract][Full Text] [Related]
12. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
